JPY 2065.0
(-0.24%)
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2023 | 5.04 Billion JPY | 6.96% |
2022 | 4.71 Billion JPY | 17.07% |
2021 | 4.02 Billion JPY | -3.57% |
2020 | 4.17 Billion JPY | -4.53% |
2019 | 4.37 Billion JPY | 0.0% |
Year | Total Liabilities | Total Liabilities Growth |
---|---|---|
2024 Q1 | 5.49 Billion JPY | 9.03% |
2023 Q2 | 5.05 Billion JPY | 2.35% |
2023 Q4 | 5.04 Billion JPY | -2.1% |
2023 Q3 | 5.14 Billion JPY | 1.92% |
2023 Q1 | 4.93 Billion JPY | 4.73% |
2023 FY | 5.04 Billion JPY | 6.96% |
2022 Q2 | 4.26 Billion JPY | 0.0% |
2022 Q4 | 4.71 Billion JPY | 9.33% |
2022 Q3 | 4.31 Billion JPY | 1.13% |
Name | Total Liabilities | Total Liabilities Difference |
---|---|---|
Pharma Foods International Co., Ltd. | 24.98 Billion JPY | 79.83% |
Takeda Pharmaceutical Company Limited | 7834.78 Billion JPY | 99.936% |
Sumitomo Pharma Co., Ltd. | 751.37 Billion JPY | 99.329% |
Shionogi & Co., Ltd. | 164.35 Billion JPY | 96.933% |
Wakamoto Pharmaceutical Co.,Ltd. | 3.39 Billion JPY | -48.455% |
Nippon Shinyaku Co., Ltd. | 42.86 Billion JPY | 88.243% |
Kaken Pharmaceutical Co., Ltd. | 27.86 Billion JPY | 81.913% |
Eisai Co., Ltd. | 494.82 Billion JPY | 98.981% |
Hisamitsu Pharmaceutical Co., Inc. | 61.69 Billion JPY | 91.831% |
Mochida Pharmaceutical Co., Ltd. | 30.83 Billion JPY | 83.653% |
Fuso Pharmaceutical Industries,Ltd. | 39.79 Billion JPY | 87.335% |
Nippon Chemiphar Co., Ltd. | 31.08 Billion JPY | 83.786% |
Tsumura & Co. | 132.88 Billion JPY | 96.207% |
Kissei Pharmaceutical Co., Ltd. | 39.79 Billion JPY | 87.334% |
Torii Pharmaceutical Co., Ltd. | 13.29 Billion JPY | 62.097% |
Towa Pharmaceutical Co., Ltd. | 274.75 Billion JPY | 98.166% |
Fuji Pharma Co., Ltd. | 44.15 Billion JPY | 88.586% |
Zeria Pharmaceutical Co., Ltd. | 70.7 Billion JPY | 92.872% |
KYORIN Holdings, Inc. | 46.89 Billion JPY | 89.252% |
Taiko Pharmaceutical Co.,Ltd. | 7 Billion JPY | 28.031% |
Daito Pharmaceutical Co.,Ltd. | 25.43 Billion JPY | 80.188% |
SymBio Pharmaceuticals Limited | 8.14 Billion JPY | 38.1% |
MedRx Co., Ltd | 129 Million JPY | -3806.977% |
Mizuho Medy Co.,Ltd. | 3.27 Billion JPY | -54.009% |
Solasia Pharma K.K. | 673 Million JPY | -648.886% |
Modalis Therapeutics Corporation | 645.5 Million JPY | -680.786% |
ASKA Pharmaceutical Holdings Co.,Ltd. | 31.38 Billion JPY | 83.939% |
Sawai Group Holdings Co., Ltd. | 163.99 Billion JPY | 96.927% |
Cyfuse Biomedical K.K. | 1.01 Billion JPY | -398.349% |
Toho Holdings Co., Ltd. | 523.98 Billion JPY | 99.038% |
Koa Shoji Holdings Co.,Ltd. | 6.95 Billion JPY | 27.506% |